Most Recent
Judge ‘uncomfortable’ with common fund order in toxic foam class actions
A judge overseeing three toxic foam class actions against the Commonwealth of Australia has said he's not comfortable approving a common fund order which does not detail specific remuneration amounts for funder IMF Bentham.
Neurim wins fight to amend patent for top-selling Circadin amid infringement case
Drug maker Neurim Pharmaceuticals has won a bid to amend its Australian patent for top selling sleeping pill Circadin over the protests of two generic pharmaceutical companies, whch argued Neurim had purposely delayed the application to gain an unfair advantage in its infringement suit.
ASIC asks High Court to clarify meaning of ‘officer’
ASIC is seeking approval from the High Court to appeal a judgment that let a former director of Gold Coast finance company MFS Group partially off the hook for $147.5 million in misappropriated funds, saying the High Court needs to clarify the scope of the word "officer" under the Corporations Act.
Toxic foam class action not time-barred, court hears
The applicants in a class action over exposure to allegedly toxic foam used on a government military base have struck back at the Commonwealth of Australia's argument that their claims were filed too late.
MFS execs lose appeal over $147.5M in misused funds
Three former executives of failed Gold Coast finance company MFS Group have lost their challenge to a ruling that they misappropriated $147.5 million in funds prior to the company's collapse.
Neurim fights to amend Circadin patent amid infringement case against generics
Drug maker Neurim Pharmaceuticals is battling to amend its Australian patent for the blockbuster sleeping pill Circadin over opposition from two generic pharmaceutical companies, which have accused Neurim of attempting to gain an unfair advantage by delaying the amendment bid until now.
Privilege not waived by DLA Piper phone call over Circadin patent
Two generic drug makers have lost their bid for confidential documents related to Neurim Pharmaceuticals' patents covering sleep drug Circadin, with a court ruling legal professional privilege was waived in a phone conversation between a DLA Piper lawyer and the company's founder.
DLA Piper’s patent advice to Neurim not privileged, court hears
Two generic drug makers are fighting for access to confidential documents related to amendments by Neurim Pharmaceutical of patents covering its sleep drug Circadin, telling the Federal Court on Thursday privilege had been waived after a phone conversation between the company's founder and her lawyers from DLA Piper.
DibbsBarker to close up shop following Dentons deal
DibbsBarker is closing its doors after signing a deal that will see 17 partners and support staff move to Dentons, the world's largest firm.
Dentons grows Aussie presence with new Melbourne digs
Global law firm Dentons has expanded its presence in Australia with a fifth office Down Under, this one in Melbourne.